Clinical trial
A Study of the Safety and Effectiveness of Different Doses of 1592U89 in…
NCT00002390 · Glaxo Wellcome, Industry · Completed
Key facts
| NCT number | NCT00002390 |
|---|---|
| Title | A Study of the Safety and Effectiveness of Different Doses of 1592U89 in HIV-Infected Patients |
| Official title | A Phase II Randomized, Blinded, Dose-Ranging Multicenter Study to Evaluate the Safety and Efficacy of Different Regimens of 1592U89 Monotherapy Upon Selected Immunological and Virological Markers of HIV-1 Infection in Antiretroviral Therapy-Naive Patients |
| Lead sponsor | Glaxo Wellcome, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | HIV Infections |
| Intervention type | Drug |
| Interventions | Abacavir sulfate |
| First posted | Aug 31, 2001 |
| Last update posted | Jun 24, 2005 |
| Countries | France, Germany |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: